Baader Bank Aktiengesellschaft Decreases Stock Holdings in ResMed Inc. $RMD

Baader Bank Aktiengesellschaft decreased its stake in shares of ResMed Inc. (NYSE:RMD) by 45.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,417 shares of the medical equipment provider’s stock after selling 8,794 shares during the period. Baader Bank Aktiengesellschaft’s holdings in ResMed were worth $2,822,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. SJS Investment Consulting Inc. lifted its holdings in shares of ResMed by 1,433.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 86 shares during the period. WFA of San Diego LLC bought a new position in ResMed in the second quarter valued at about $26,000. Westside Investment Management Inc. lifted its holdings in ResMed by 100.0% in the third quarter. Westside Investment Management Inc. now owns 132 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 66 shares during the period. GoalVest Advisory LLC purchased a new position in ResMed in the third quarter worth about $37,000. Finally, Winnow Wealth LLC bought a new stake in shares of ResMed during the 3rd quarter valued at about $54,000. Institutional investors own 54.98% of the company’s stock.

Insiders Place Their Bets

In related news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $251.31, for a total value of $502,620.00. Following the completion of the transaction, the director owned 64,773 shares in the company, valued at approximately $16,278,102.63. This trade represents a 3.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael J. Farrell sold 4,991 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $248.46, for a total value of $1,240,063.86. Following the sale, the chief executive officer owned 466,223 shares in the company, valued at approximately $115,837,766.58. This trade represents a 1.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 18,137 shares of company stock valued at $4,658,832 in the last three months. Corporate insiders own 0.65% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on RMD shares. Wall Street Zen upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research note on Saturday. Mizuho dropped their price target on shares of ResMed from $310.00 to $300.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Citigroup boosted their price objective on shares of ResMed from $330.00 to $345.00 and gave the company a “buy” rating in a research report on Monday, February 2nd. Weiss Ratings raised ResMed from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday. Finally, Stifel Nicolaus lifted their target price on ResMed from $260.00 to $265.00 and gave the company a “hold” rating in a research report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, ResMed presently has an average rating of “Moderate Buy” and a consensus target price of $299.27.

ResMed Price Performance

NYSE:RMD opened at $263.21 on Wednesday. The company has a current ratio of 3.06, a quick ratio of 2.32 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $38.34 billion, a P/E ratio of 26.03, a P/E/G ratio of 1.83 and a beta of 0.87. ResMed Inc. has a 12 month low of $199.92 and a 12 month high of $293.81. The business’s 50-day moving average is $252.58 and its 200 day moving average is $263.24.

ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. The business had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.40 billion. ResMed had a return on equity of 25.20% and a net margin of 27.53%.The company’s revenue was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.43 EPS. On average, equities research analysts forecast that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Thursday, February 12th will be given a dividend of $0.60 per share. The ex-dividend date is Thursday, February 12th. This represents a $2.40 annualized dividend and a yield of 0.9%. ResMed’s dividend payout ratio (DPR) is 23.74%.

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.